ADC Therapeutics Quote - ADCT

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

1.98

Bid

Ask

Volume

708

0.00 Day's Range 0.00

0.684 52 Week Range 6.04

Market Cap

191.445M

Previous Close

1.98

Open

Last Trade

200

1.98

(formt)

Last Trade Time

08:09:53

Financial Volume

VWAP

Average Volume (3m)

377,803

Shares Outstanding

96,689,617

Dividend Yield

PE Ratio

-0.82

Earnings Per Share (EPS)

-2.43

Revenue

69.56M

Net Profit

-234.53M

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602,... ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212. Show more

Sector

Drugs And Proprietary-whsl

Industry

Drugs And Proprietary-whsl

Website

www.adctherapeutics.com

Headquarters

Lausanne, Che

Founded

ADC Therapeutics SA is listed in the Drugs And Proprietary-whsl sector of the New York Stock Exchange with ticker ADCT. The last closing price for ADC Therapeutics was US$1.98. Over the last year, ADC Therapeutics shares have traded in a share price range of US$ 0.684 to US$ 6.04.

ADC Therapeutics currently has 96,689,617 shares outstanding. The market capitalization of ADC Therapeutics is US$191.45 million. ADC Therapeutics has a price to earnings ratio (PE ratio) of -0.82.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update PR Newswire LAUSANNE, Switzerland, Nov. 7, 2024 LOTIS-5 full enrollment and LOTIS-7...

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting PR Newswire LAUSANNE, Switzerland, Nov. 5, 2024 Oral presentation of...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.84	-29.7872340426	2.82	2.87	1.885	492994	2.23832581	CS
4	-1.01	-33.779264214	2.99	3.3	1.885	431506	2.76163612	CS
12	-1	-33.5570469799	2.98	3.45	1.885	377803	2.93821082	CS
26	-2.12	-51.7073170732	4.1	4.17	1.885	472882	3.14820895	CS
52	1.28	182.857142857	0.7	6.04	0.684	608428	3.22586574	CS
156	-20.85	-91.3272010512	22.83	23.2832	0.359908	470507	4.03393337	CS
260	-28.02	-93.4	30	56.5899	0.359908	397269	9.64404765	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AAMAA Mission Acquisition Corp	US$ 10.0507 (0.00%)	0
AACT.UAres Acquisition Corporation II	US$ 10.93 (0.00%)	0
AACTAres Acquisition Corporation II	US$ 10.89 (0.00%)	0
AAAlcoa Corporation	US$ 45.74 (0.00%)	12.84k
AAgilent Technologies	US$ 128.57 (0.00%)	4.93k
AAMAA Mission Acquisition Corp	US$ 10.0507 (0.00%)	0
AACT.UAres Acquisition Corporation II	US$ 10.93 (0.00%)	0
AACTAres Acquisition Corporation II	US$ 10.89 (0.00%)	0
AAAlcoa Corporation	US$ 45.74 (0.00%)	12.84k
AAgilent Technologies	US$ 128.57 (0.00%)	4.93k
CTVInnovid Corp	US$ 1.62 (0.00%)	7M
SNOWSnowflake Inc	US$ 129.12 (0.00%)	2.3M
TOSTToast Inc	US$ 42.50 (0.00%)	2.08M
PLTRPalantir Technologies Inc	US$ 62.12 (0.00%)	1.74M
NIONIO Inc	US$ 4.65 (0.00%)	1.47M